A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
NCT06820723
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Depression
- Anxiety
- Major Depressive Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ohio State University
- Last updated on ClinicalTrials.gov
- July 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Ohio · 1
- The Ohio State University Department of Psychiatry · Columbus, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.